MADIT-CRT: Good News for Devices in Heart Failure, But Will Referring Physicians Care?
Proponents of cardiac resynchronization devices with a defibrillation function expect the recently released results of the MADIT-CRT trial to give a long-awaited boost to the overall implantable cardioverter defibrillator market. Boston Scientific Corp., the sponsor of the study, expects the FDA to soon expand the indication for its CRT devices to the roughly 70% of heart failure patients worldwide in New York Heart Association heart failure Class I or Class II, reflecting the improvements in hospitalization and ventricular output linked to CRT in the trial.
You may also be interested in...
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.
If President Donald Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsburg, Affordable Care Act coverage could disappear. Two legal experts weigh in on this and other legal issues that could touch the medical device industry.
The Dutch start-up will use the funds to finalize product design for a neurostimulation platform targeting chronic migraines.